Skip to search formSkip to main contentSkip to account menu

ponatinib 45 MG Oral Tablet [Iclusig]

Known as: Iclusig (as ponatinib hydrochloride) 45 MG Oral Tablet, Iclusig 45 MG Oral Tablet, ponatinib hydrochloride 45 mg ORAL TABLET, FILM COATED [Iclusig] 
National Institutes of Health

Related topics

Related topics

8 relations
IclusigLactose MonohydrateMagnesium stearateOral Tablet

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
LC-ESI-MS/MS identification and characterization of ponatinib in vivo phase I and phase II metabolites.
2017
2017
Pharmacological characteristics and clinical outcomes of ponatinib (Iclusig®), a third-generation tyrosine kinase inhibitor.
2017
2017
Erratum: Pharmacological characteristics and clinical outcomes of ponatinib (Iclusig®), a third-generation tyrosine kinase inhibitor.
  • Nihon yakurigaku zasshi. Folia pharmacologica…
  • 2017
  • Corpus ID: 38618816
2016
2016
Ponatinib in chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia: a guide to its use in the EU
Oral ponatinib (Iclusig®) is a novel kinase inhibitor that was designed to overcome resistance mutations in the ABL kinase domain… 
2014
2014
Ponatinib (Iclusig®.): nuevas recomendaciones sobre el riesgo de acontecimientos vasculares oclusivos
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)